Webinars and Events | May 24, 2023

New Drugs to Treat Obesity: What Plan Sponsors Need to Know

The latest generation of prescription drugs originally developed to help people manage their type 2 diabetes, such as Ozempic®, have been causing quite a stir for patients, health professionals and benefit plans now that some have been both approved and promoted for treating obesity. The effectiveness of and demand for these newer drugs are prompting some plan sponsors that exclude anti-obesity drugs from coverage to revisit plan rules. However, there are concerns about the potentially large target patient population, as well as the increased utilization and the high cost of these drugs.

This webinar addresses the range of issues plan sponsors face related to weight-loss benefits and potential coverage of newer anti-obesity drug therapies.

Black Senior Man Listens To His Doctor Talk About His Treatment Plan

You’ll gain an understanding of

  • The history behind glucagon-like peptide-1 or GLP-1 medications and their on- and off-label use
  • How GLP-1 medication usage trends are impacting benefit plans
  • Ways to better manage the rising utilization and cost of GLP-1 medications
  • How federal laws like the Mental Health Parity and Addiction Equity Act affect coverage decisions
  • What to consider before deciding to cover anti-obesity medications, including the importance of incorporating behavioral health programs into your strategy

Webinar Replay

 

Speakers

Eileen Pincay
Eileen Pincay, RPh
Vice President 
National Pharmacy Practice Leader
Sadhna Paralkar
Sadhna Paralkar, MD
Senior Vice President
National Medical Director
Elena Lynett
Elena Lynett
Vice President
National Health Compliance Group

Get the Slides

Don’t have time to watch a video right now? No worries. Here is a copy of the slides from this session.

Download Now

See more insights

Doctor Giving Prescription To Woman

New Drugs for Weight Loss: What Plan Sponsors Need to Know

Learn about the new weight-loss drugs and get cost-management tips.

Health, Benefits Administration, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Pharmaceutical, Corporate

Read Full Insight

Depressed Man Visits To Virtual Psychotherapis

5 Key Considerations for Behavioral Health Solutions

Learn about a systematic strategy to help you make confident choices.

Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Corporate, Architecture Engineering & Construction

Read Full Insight

A Woman Discusses With Her Doctor About Possibilities For Diabetes Treatment

Health Plan News Q2 2023

Biosimilars will change the treatment landscape, allowing plan sponsors to greatly reduce costs. Get strategies for encouraging use of biosimilars.

Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Corporate

Read Full Insight

This page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.

Don't miss out. Join 16,000 others who already get the latest insights from Segal.